Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of XC101-D13H in Healthy Adults
NCT04104399Phase 1Unknown
- Sponsor
- Xoc Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in migraine comparing XC101-D13H with Placebo (2 arms). Primary endpoint: Incidence and Severity of Adverse Events. Status: unknown.
02
Drugs
XC101-D13H
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04104399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04104399.